Menquadfi 55 mcg (Tetanus Toxoid SOLUTION) 55 MCG

MENQUADFI 55 MCG is a tetanus toxoid solution designed for intramuscular administration. This vaccine is used to prevent tetanus, a serious bacterial infection. It is manufactured by Sanofi Pasteur Limited in Canada.

Strength

55 MCG

Manufacturer / TM Owner

SANOFI PASTEUR LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

MENQUADFI 55 MCG is primarily used for the prevention of tetanus, a potentially life-threatening condition caused by bacterial toxins. This vaccine is often recommended for individuals who are at risk of tetanus infection, such as those with wounds or injuries that could be contaminated. It works by stimulating the body's immune system to produce antibodies against the tetanus toxin.

Side Effects

Common effects of MENQUADFI 55 MCG may include mild redness, swelling, or pain at the injection site. Some individuals might experience temporary fever, headache, or muscle aches. These effects are usually mild and resolve on their own within a few days.

Precautions & Warnings

Before receiving MENQUADFI 55 MCG, inform your healthcare provider about any allergies or medical conditions. It is important to follow the recommended storage and handling instructions to maintain the vaccine's effectiveness. Always consult a healthcare professional for personalized advice.

Avoid Interactions

MENQUADFI 55 MCG may interact with certain medications or other vaccines. It is advisable to discuss your current medications with a healthcare provider before receiving this vaccine. Avoid taking alcohol or other substances that may affect your immune system without consulting a healthcare professional.

Frequently Asked Questions

MENQUADFI 55 MCG is used to prevent tetanus, a serious bacterial infection caused by toxins.

MENQUADFI 55 MCG is administered intramuscularly, typically in the upper arm or thigh.

Common side effects may include mild redness, swelling, or pain at the injection site, as well as temporary fever or muscle aches.

It is important to discuss your current medications with a healthcare provider to avoid potential interactions.

Individuals with a history of severe allergic reactions to tetanus toxoid or any component of the vaccine should avoid MENQUADFI 55 MCG.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.